

## Supplementary Data

SUPPLEMENTARY TABLE S1. BASELINE CHARACTERISTICS CONSIDERING PRESENCE OF HEPATIC STEATOSIS

<i>Patient characteristics (n = 247)</i>	<i>All patients (n = 247)</i>	<i>No steatosis (n = 171)</i>	<i>Steatosis of any grade (n = 76)</i>	<i>p</i>
<b>Epidemiological characteristics</b>				
<b>Sex</b>				
Male, % (n/all)	75 (185/247)	78 (133/171)	68 (52/76)	0.118
Age (years)	43.3 ± 9.97	42.3 ± 10.2	45.5 ± 9.21	<b>0.020</b>
<b>Ethnicity, % (n/all)</b>				
Caucasian	96 (238/247)	96 (165/171)	96 (73/76)	1
African American	2 (4/247)	1 (2/171)	3 (2/76)	0.589
Hispanic	1 (2/247)	1 (1/171)	1 (1/76)	0.522
Asian	1 (3/247)	2 (3/171)	0 (0/76)	0.555
<b>Transmission, % (n/all)</b>				
MSM	30 (73/247)	38 (65/171)	11 (8/76)	<b>&lt;0.001</b>
PWID	55 (135/247)	47 (81/171)	71 (54/76)	
Others	16 (39/247)	15 (25/171)	18 (14/76)	
Weight (kg)	70.6 ± 15.1	68.4 ± 13.2	75.5 ± 17.7	<b>0.001</b>
BMI (kg/m <sup>2</sup> )	23.3 ± 4.27	22.6 ± 3.79	24.9 ± 4.83	<b>&lt;0.001</b>
DM, % (n/all)	3 (8/247)	3 (5/171)	4 (3/76)	0.705
Hypertension, % (n/all)	9 (22/247)	8 (14/171)	11 (8/76)	0.561
<b>PNPLA3, % (n/all)</b>				
CC	52 (110/213)	56 (80/144)	43 (30/69)	0.099
GG	4 (9/213)	3 (4/144)	7 (5/69)	0.151
<b>Laboratory parameters</b>				
Platelet count (G/L)	209 ± 80.3	216 ± 84.8	194 ± 67.2	0.055
Prothrombin time (%)	89.0 (23.3)	89.0 (23.0)	89.5 (27.3)	0.459
Bilirubin (mg/dL)	0.47 (0.35)	0.46 (0.31)	0.54 (0.40)	0.062
Albumin (g/dL)	43.9 ± 4.26	43.7 ± 4.56	44.4 ± 3.45	0.245
AST (IU/L)	46.0 (42.0)	47.0 (47.0)	43.5 (38.8)	0.193
ALT (IU/L)	50.0 (65.0)	53.0 (78.0)	46.0 (49.8)	<b>0.038</b>
GGT (IU/L)	68.0 (106)	63.0 (101)	73.5 (114)	0.498
TG (mg/dL)	98.0 (66.5)	96.0 (69.5)	105 (61.0)	0.283
TCHOL (mg/dL)	158 ± 40.1	156 ± 36.7	161 ± 46.8	0.428
HDL (mg/dL)	47.7 ± 18.6	47.3 ± 17.3	48.6 ± 21.2	0.632
LDL (mg/dL)	86.5 ± 33.3	85.5 ± 31.7	88.5 ± 36.5	0.532
HOMA-IR	2.61 (2.94)	2.32 (3.69)	3.32 (2.17)	<b>0.047</b>
FIB-4	1.37 (1.22)	1.29 (1.04)	1.61 (1.47)	<b>0.024</b>
APRI	0.50 (0.62)	0.48 (0.63)	0.57 (0.62)	0.704
<b>HIV infection parameters</b>				
Time since diagnosis of HIV (years)	11.3 (13.7)	9.87 (11.0)	14.1 (18.4)	<b>0.007</b>
CD4 <sup>+</sup> T lymphocyte count (cells/μL)	572 ± 318	586 ± 330	542 ± 289	0.330
CD4 <sup>+</sup> /CD8 <sup>+</sup>	0.68 (0.49)	0.69 (0.46)	0.67 (0.54)	0.793
HIV-RNA <50 copies/mL	82% (199/243)	81% (136/168)	84% (63/75)	0.569
HIV-RNA <400 copies/mL	92% (223/243)	90% (152/168)	95% (71/75)	0.272
<b>ART, % (n/all)</b>				
PI	20 (47/241)	11 (18/167)	39 (29/74)	<b>&lt;0.001</b>
N(t)RTI	95 (230/241)	97 (162/167)	92 (68/74)	0.079
NNRTI	23 (56/241)	25 (41/167)	20 (15/74)	0.468
INSTI	60 (145/241)	66 (110/167)	47 (35/74)	<b>0.007</b>
Time on ART (years)	6.19 (9.92)	5.86 (8.44)	7.95 (14.6)	0.072

(continued)

SUPPLEMENTARY TABLE S1. (CONTINUED)

<i>Patient characteristics (n=247)</i>	<i>All patients (n=247)</i>	<i>No steatosis (n=171)</i>	<i>Steatosis of any grade (n=76)</i>	<i>p</i>
<b>HCV infection parameters</b>				
Time since diagnosis of HCV (years)	7.17 (15.2)	5.61 (14.1)	10.7 (14.5)	<b>0.003</b>
HCV-RNA (log IU/mL)	6.05 (1.24)	6.04 (1.31)	6.06 (1.14)	0.879
<b>HCV-GT, % (n/all)</b>				
1a	49 (120/245)	52 (88/170)	43 (32/75)	0.546
1b	16 (40/245)	14 (24/170)	21 (16/75)	
2	2 (6/245)	2 (4/170)	3 (2/75)	
3	23 (56/245)	22 (37/170)	25 (19/75)	
4	9 (23/245)	10 (17/170)	8 (6/75)	
<b>Liver stiffness, % (n/all)</b>				
F0/F1 (<7.1 kPa)	46 (114/247)	50 (85/171)	38 (29/76)	0.093
F2 (≥7.1 and <9.5 kPa)	27 (67/247)	26 (45/171)	29 (22/76)	0.668
F3 (≥9.5 and <12.5 kPa)	13 (33/247)	12 (21/171)	16 (12/76)	0.454
F4 (≥12.5 kPa)	13 (33/247)	12 (20/171)	17 (13/76)	0.249
TE (kPa)	7.50 (4.10)	7.10 (3.90)	8.55 (4.00)	<b>0.014</b>

Bold *p* values denote statistical significance.

ALT, alanine transaminase; aOR, adjusted odds ratio; APRI, AST to Platelet Ratio Index; ART, antiretroviral therapy; AST, aspartate transaminase; BMI, body mass index; CAP, controlled attenuation parameter; DM, diabetes mellitus; FIB-4, Fibrosis-4 Score; GGT, gamma-glutamyl transpeptidase; GT, genotype; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model assessment for insulin resistance; INSTI, integrase inhibitor; LDL, low-density lipoprotein; MSM, men who have sex with men; NNRTI, non-nucleoside reverse-transcriptase inhibitor; N(t)RTI, nucleos(t)idic reverse transcriptase inhibitor; PI, protease inhibitor; PNPLA3, patatin-like phospholipase domain containing 3; PWID, people who inject drugs; TCHOL, total cholesterol; TE, transient elastography; TG, triglyceride.